论文部分内容阅读
对维拉帕米(VR)治疗室上快速型心律失常(SVT)时红细胞钙泵和Ca~(2+)变化进行对比研究,正常人30名红细胞内Ca~(2+)为0.32±0.02μmol/gHb,红细胞膜钙泵为44.1±1.8μmolPi/gHb/h.SVT53例发病时,红细胞内Ca~(2+)为0.47±002μmol/gHb,膜钙泵为67.5±2.5μmolPi/glib/h,明显高于正常人(均为P<0.001),给VR后,红细胞内Ca~(2+)降至正常水平(P>0.05),但膜钙泵活力仍超出正常水平(P<0.01).结果表明VR主要阻滞细胞膜Ca~(2+)内流,并对钙泵有轻度抑制作用.SVT病人个体间血浆VR浓度差异较大,总的血浆VR浓度与临床效应无一致性变化。
To compare the changes of erythrocyte calcium pump and Ca ~ (2+) in verapamil (VR) treatment of supraventricular tachyarrhythmia (SVT), the Ca ~ (2+) in 30 erythrocytes of normal people was 0.32 ± 0.02 μmol / gHb, the erythrocyte membrane calcium pump was 44.1 ± 1.8μmolPi / gHb / h.SVT 53 cases of intracranial erythrocytes Ca2 + was 0.47 ± 002μmol / gHb, membrane calcium pump 67.5 ± 2.5μmolPi / glib / h (P <0.001), and the level of Ca2 + in erythrocytes decreased to normal level (P> 0.05), but the activity of membrane calcium pump still exceeded the normal level (P <0.01) .The results showed that VR mainly blocked the influx of Ca 2+ in the cell membrane and mildly inhibited the calcium pump.The plasma VR concentration in patients with SVT varied greatly and there was no consistency between the total plasma VR concentration and the clinical effect .